Clinical Trial Update: To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study from UCB Pharma evaluated blood levels and safety of CDP6038 in rheumatoid arthritis patients using methotrexate.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CDP6038

Snippet

Sponsor: UCB Pharma | Conditions: Arthritis, Rheumatoid Arthritis | Phase 1, Phase 2 | Status: COMPLETED